Skip to Main Content

Paper Details

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Nat Med
166
2021
Alzheimer's disease, Amyloid-related imaging abnormalities, DIAD, Gantenerumab, amyloid, cerebrospinal fluid, edema, gantenerumab, neurofilament light chain, participants, phospho, phospho-tau181, solanezumab, tau
Author NameAffiliation
Stephen SallowayWarren Alpert Medical School of Brown University
Martin R FarlowIndiana University School of Medicine
Eric McDadeWashington University School of Medicine
David B CliffordWashington University School of Medicine
Alison M GoateIcahn School of Medicine at Mount Sinai
John C MorrisWashington University School of Medicine
James J LahEmory University Medical Center
Christopher H van DyckYale University School of Medicine
Lawrence S HonigColumbia University Medical Center
Douglas GalaskoUniversity of California San Diego
Ging-Yuek R HsiungUniversity of British Columbia
Suman JayadevUniversity of Washington School of Medicine
Clifford R JackMayo Clinic
Robert A KoeppeUniversity of Michigan ann arbor
Peter J SnyderUniversity of Rhode Island
Paul S AisenKeck School of Medicine, University of Southern California
Ronald G ThomasUniversity of California San Diego
Scott M Berry
Mark A Mintun
Rachelle S DoodyF. Hoffmann-La Roche Ltd
  • 1 - 20

Datasets

Release 1.2